In addition, another independent validation set with 198 BC samples were also analysed in order to identify new biomarker to predict response and prognosis for HER2-negative BC patients who received sequential taxane-anthracycline neoadjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.